Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

Introduction: PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality. Methods: A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were given olaparib 300 mg twice daily in a 21-day cycle...

Full description

Bibliographic Details
Main Authors: Azam Ghafoor, MD, Idrees Mian, MD, Cathy Wagner, BSN, Yvonne Mallory, BSN, Maria Garcia Agra, BSN, Betsy Morrow, BS, Jun S. Wei, PhD, Javed Khan, MD, Anish Thomas, M.B.B.S., MD, Manjistha Sengupta, PhD, Seth M. Steinberg, PhD, Raffit Hassan, MD
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:JTO Clinical and Research Reports
Subjects:
Mesothelioma
PARPI
Olaparib
BAP1
MRE11A
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000904

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000904

Similar Items